The UK has set out a strategy to replace animal testing, but delivering change will depend as much on regulation as on technology. Dr Emma Grange, Director of Science and Regulatory Affairs at Cruelty Free International, examines what the policy signals for research, drug discovery and safety assessment.

AI in drug discovery is no longer theoretical. It’s already speeding up predictions, improving outcomes and cutting waste. Learn how to apply it in your own discovery pipeline.

A team of researchers has developed a faster, simpler method for creating non-natural amino acids and assemble them into peptides, a breakthrough that could accelerate peptide research and provide new tools for designing drugs.

Lario Therapeutics has secured $2.4 million in funding from The Michael J. Fox Foundation for Parkinson’s Research and Wellcome to accelerate development of its neuronal calcium channel platform.

A study from the Institut Pasteur reveals how cellular senescence during mammary gland involution after pregnancy may both aid tissue repair and promote postpartum breast cancer.

A University of Houston scientist has joined a $3.2 million research collaboration to develop a new drug targeting one of the key drivers of triple-negative breast cancer.

A new research collaboration between Insilico Medicine and Memorial Sloan Kettering Cancer Center aims to harness generative AI technology to identify novel therapeutic targets for gastroesophageal cancers.

A rare liver cancer that primarily affects young people may soon have a new treatment option, after researchers found that an existing FDA-approved drug could enable immunotherapy to work effectively against tumours.

Early drug discovery has no shortage of genomic data, but confidence remains scarce. This report examines how CRISPR, functional genomics and human-relevant models are being applied to determine which signals matter, how they influence disease biology and which targets and strategies are worth pursuing.

Automation now plays a central role in discovery. From self-driving laboratories to real-time bioprocessing, this report explores how data-driven systems improve reproducibility, speed decisions and make scale achievable across research and development.

Biomarkers are redefining how precision therapies are discovered, validated and delivered. This exclusive expert-led report reveals how leading teams are using biomarker science to drive faster insights, cleaner data and more targeted treatments – from discovery to diagnostics.

Explore how artificial intelligence (AI), biomarkers, and innovative trial technologies are creating a more efficient, data-driven future for drug discovery. From better patient selection to smarter trial design, see how clinical research is evolving to deliver new therapies faster.